Feasibility of creating a daily adaptive plan using automatic DIR-created target and OARs contours in patients with prostate cancer magnetic-resonance-guided adaptive radiotherapy

J Radiat Res. 2024 Nov 11:rrae088. doi: 10.1093/jrr/rrae088. Online ahead of print.

Abstract

The purpose of this study was to evaluate the feasibility of treatment plans for prostate cancer with magnetic resonance (MR)-guided online adaptive radiotherapy, which are generated using deformable image registration (DIR)-created contours of the targets and organs. Totally, 150 fractions from 30 prostate cancer patients implanted with a hydrogel spacer and treated with the MR-Linac were studied. Reference treatment plans that satisfied all institutional dose constraints were initially created on planning MRI. The adaptive treatment plans were created on daily MRI based on the reference plan using the DIR-created contours, ensuring all dose constraints were met. Subsequently, a clinician manually created reference contours for each daily MRI. Finally, the dose volume histogram indices of the plan generated with DIR-created contours were re-evaluated with clinician created contours. The evaluated contours included the bladder wall, rectum wall, sigmoid, small bowel and planning target volume (PTV) for dose prescription. The PTV for dose prescription met the dose constraints in all fractions. The bladder and rectum walls met the dose constraint of maximum dose (D0.03 cc) in all fractions. Five patients failed to meet the sigmoid and small bowel dose constraints, with the largest deviation being 13.3% exceedance at D2 cc in the small bowel added 3 mm margin. This study suggests that most treatment plans created without modifying the DIR-created contours are clinically viable. However, dislodgements of the small bowel and sigmoid may exceed the extent of DIR propagation from the reference plan contours, and it is recommended that these contours be verified.

Keywords: MR-Linac; MR-guided online adaptive radiotherapy; deformable image registration; prostate cancer; stereotactic body radiotherapy (SBRT).

Grants and funding